A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma. Cohorts of 3-6 patients will be assessed for dose limiting toxicities (DLTs) during Cycle 1 until the maximum tolerated dose (MTD) of the combination therapy is determined. The MTD or Phase 2 Recommended Dose (P2RD) will be used in a Phase II part of the study, which will enrol 55 patients each into two randomized groups: the combination therapy or MEK162 alone. The Phase II part will continue until proof of concept is established. Patients will continue treatment as long as clinical benefit is seen and no limiting adverse toxicity is observed

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

NCT05496686

Uveal Melanoma Metastatic

RECRUITING PHASE1

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085

BRAF or NRAS Mutant Metastatic Melanoma

COMPLETED PHASE2

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162

Melanoma

TERMINATED PHASE2

Intermittent Selumetinib for Uveal Melanoma

NCT02768766

Uveal Melanoma

COMPLETED PHASE1

Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

NCT00093119

Melanoma Metastases

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Due to halted enrollment, the Phase II part of the study was not conducted. The Sponsor decided to permanently stop recruitment for the study prior to MTD determination.

Remaining patients on treatment with binimetinib and sotrastaurin who were considered by the Investigator to be benefiting from their treatment could have continued treatment and were to be followed up as per protocol. No patients were ongoing as of the data cut-off date. After the last patient last visit (LPLV) was declared, the study was terminated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveal Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

AEB071 and MEK162 combined

Group Type EXPERIMENTAL

AEB071

Intervention Type DRUG

Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)

MEK162

Intervention Type DRUG

Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)

Arm B

MEK162 alone

Group Type EXPERIMENTAL

MEK162

Intervention Type DRUG

Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AEB071

Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)

Intervention Type DRUG

MEK162

Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sotrastaurin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Male and female patients aged 18 years or older
* A history of uveal (ocular) melanoma with biopsy-confirmed metastatic disease
* Consent to providing 3 tumor biopsy samples throughout the course of the study
* Presence of measurable disease
* A WHO performance status of less than or equal to 1

Exclusion Criteria

* Presence of CNS lesions (stable lesions may be acceptable)
* Previous or concurrent malignancy, other than basal cell or squamous cell carcinoma of the skin: in situ carcinoma of the cervix, without evidence of recurrence for at least 3 years; a primary malignancy completely resected and no evidence of recurrence for at least 3 years
* Adverse event from prior chemotherapy, radiotherapy or surgery that has not recovered to CTCAE v4.03 Grade 1 or less, except for alopecia/sensory peripheral neuropathy, which must be less than Grade 2
* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO
* Impaired cardiac function or clinically significant cardiac disease
* Impaired GI function or disease that could interfere with the absorption of AEB071 and/or MEK162
* Treatment with medicines or herbal supplements that are known inhibitors or inducers of CYP3A4/5 and cannot be withdrawn prior to study treatment
* Females of child-bearing potential who are unwilling or unable to use highly effective means of contraception
* Males who are unwilling or unable to use a condom during sexual intercourse

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No